Jubilant Life Sciences has announced that its subsidiary Jubilant Pharma Limited has initiated Optimum trial, which is a pivotal Phase II clinical trial, designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma. This will be taking place through Jubilant Pharma's unit Jubilant DraxImage Inc. in Montreal, Canada.